25 XP   0   0   10

Nascent Biotech Inc
Buy, Hold or Sell?

Let's analyse Nascent Biotech Inc together

PenkeI guess you are interested in Nascent Biotech Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Nascent Biotech Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Nascent Biotech Inc

I send you an email if I find something interesting about Nascent Biotech Inc.

Quick analysis of Nascent Biotech Inc (30 sec.)










What can you expect buying and holding a share of Nascent Biotech Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.00
Expected worth in 1 year
$0.01
How sure are you?
44.8%

+ What do you gain per year?

Total Gains per Share
$0.01
Return On Investment
8.9%

For what price can you sell your share?

Current Price per Share
$0.09
Expected price per share
$0.075 - $0.28
How sure are you?
50%

1. Valuation of Nascent Biotech Inc (5 min.)




Live pricePrice per Share (EOD)

$0.09

Intrinsic Value Per Share

$-0.06 - $-0.07

Total Value Per Share

$-0.06 - $-0.07

2. Growth of Nascent Biotech Inc (5 min.)




Is Nascent Biotech Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$30.3k-$1.1m$558.2k92.0%

How much money is Nascent Biotech Inc making?

Current yearPrevious yearGrowGrow %
Making money-$523.2k-$672.3k$149k28.5%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Nascent Biotech Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#869 / 1016

Most Revenue
#778 / 1016

Most Profit
#208 / 1016

Most Efficient
#223 / 1016

What can you expect buying and holding a share of Nascent Biotech Inc? (5 min.)

Welcome investor! Nascent Biotech Inc's management wants to use your money to grow the business. In return you get a share of Nascent Biotech Inc.

What can you expect buying and holding a share of Nascent Biotech Inc?

First you should know what it really means to hold a share of Nascent Biotech Inc. And how you can make/lose money.

Speculation

The Price per Share of Nascent Biotech Inc is $0.0923. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Nascent Biotech Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Nascent Biotech Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.00. Based on the TTM, the Book Value Change Per Share is $0.00 per quarter. Based on the YOY, the Book Value Change Per Share is $0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Nascent Biotech Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.00-1.3%0.00-3.3%0.00-4.3%0.00-3.2%0.00-2.8%
Usd Book Value Change Per Share0.000.2%0.002.2%0.00-1.5%0.000.2%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.000.2%0.002.2%0.00-1.5%0.000.2%0.000.0%
Usd Price Per Share0.17-0.10-0.21-0.12-0.17-
Price to Earnings Ratio-35.72--12.67--29.09--13.18--773.58-
Price-to-Total Gains Ratio797.95-254.24--21.90-193.39--445.03-
Price to Book Ratio966.39--594.84--29.53--136.16--1,677.00-
Price-to-Total Gains Ratio797.95-254.24--21.90-193.39--445.03-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0923
Number of shares10834
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (10834 shares)22.251.66
Gains per Year (10834 shares)89.016.66
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10897907-3
201781680134
3026725702011
4035634602718
5044543503325
6053452404032
7062361304739
8071270205346
9080179106053
10089088006760

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%2.010.00.016.7%2.018.00.010.0%2.027.00.06.9%2.027.00.06.9%
Book Value Change Per Share4.00.00.0100.0%7.05.00.058.3%10.010.00.050.0%13.016.00.044.8%13.016.00.044.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.029.00.0%0.00.029.00.0%
Total Gains per Share4.00.00.0100.0%7.05.00.058.3%10.010.00.050.0%13.016.00.044.8%13.016.00.044.8%

Fundamentals of Nascent Biotech Inc

About Nascent Biotech Inc

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. In addition, it develops CLNH5. The company has collaboration with Hypospray Pharma to develop an alternative delivery mechanism for patients who can benefit from Pritumumab. Nascent Biotech, Inc. is based in North Palm Beach, Florida.

Fundamental data was last updated by Penke on 2024-04-01 23:33:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Nascent Biotech Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Nascent Biotech Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Nascent Biotech Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Nascent Biotech Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y5.5%-5.5%
5Y5.5%10Y3.8%+1.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--197.2%+197.2%
TTM--210.4%+210.4%
YOY--279.3%+279.3%
5Y5.5%-436.8%+442.3%
10Y3.8%-599.3%+603.1%
1.1.2. Return on Assets

Shows how efficient Nascent Biotech Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Nascent Biotech Inc to the Biotechnology industry mean.
  • -32.0% Return on Assets means that Nascent Biotech Inc generated $-0.32 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Nascent Biotech Inc:

  • The MRQ is -32.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -249.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-32.0%TTM-249.8%+217.8%
TTM-249.8%YOY-313.7%+63.9%
TTM-249.8%5Y-8,848.9%+8,599.1%
5Y-8,848.9%10Y-6,185.3%-2,663.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-32.0%-13.6%-18.4%
TTM-249.8%-12.9%-236.9%
YOY-313.7%-11.9%-301.8%
5Y-8,848.9%-14.2%-8,834.7%
10Y-6,185.3%-16.2%-6,169.1%
1.1.3. Return on Equity

Shows how efficient Nascent Biotech Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Nascent Biotech Inc to the Biotechnology industry mean.
  • -676.4% Return on Equity means Nascent Biotech Inc generated $-6.76 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Nascent Biotech Inc:

  • The MRQ is -676.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -169.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-676.4%TTM-169.1%-507.3%
TTM-169.1%YOY--169.1%
TTM-169.1%5Y-33.8%-135.3%
5Y-33.8%10Y-34.5%+0.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-676.4%-17.0%-659.4%
TTM-169.1%-16.1%-153.0%
YOY--15.4%+15.4%
5Y-33.8%-20.0%-13.8%
10Y-34.5%-21.1%-13.4%

1.2. Operating Efficiency of Nascent Biotech Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Nascent Biotech Inc is operating .

  • Measures how much profit Nascent Biotech Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Nascent Biotech Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Nascent Biotech Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y4.9%-4.9%
5Y4.9%10Y3.4%+1.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.1%+286.1%
TTM--224.4%+224.4%
YOY--288.4%+288.4%
5Y4.9%-475.2%+480.1%
10Y3.4%-624.7%+628.1%
1.2.2. Operating Ratio

Measures how efficient Nascent Biotech Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Nascent Biotech Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y0.051-0.051
5Y0.05110Y0.035+0.016
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.997-2.997
TTM-3.247-3.247
YOY-3.766-3.766
5Y0.0515.675-5.624
10Y0.0357.857-7.822

1.3. Liquidity of Nascent Biotech Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Nascent Biotech Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.05 means the company has $1.05 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Nascent Biotech Inc:

  • The MRQ is 1.050. The company is just able to pay all its short-term debts.
  • The TTM is 0.568. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ1.050TTM0.568+0.482
TTM0.568YOY0.261+0.307
TTM0.5685Y0.265+0.303
5Y0.26510Y0.491-0.226
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0503.930-2.880
TTM0.5684.251-3.683
YOY0.2615.436-5.175
5Y0.2656.045-5.780
10Y0.4916.363-5.872
1.3.2. Quick Ratio

Measures if Nascent Biotech Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Nascent Biotech Inc to the Biotechnology industry mean.
  • A Quick Ratio of 0.00 means the company can pay off $0.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Nascent Biotech Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y0.110-0.110
5Y0.11010Y0.076+0.034
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.629-3.629
TTM-4.065-4.065
YOY-5.397-5.397
5Y0.1105.993-5.883
10Y0.0766.277-6.201

1.4. Solvency of Nascent Biotech Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Nascent Biotech Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Nascent Biotech Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.95 means that Nascent Biotech Inc assets are financed with 95.3% credit (debt) and the remaining percentage (100% - 95.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Nascent Biotech Inc:

  • The MRQ is 0.953. The company is just able to pay all its debts by selling its assets.
  • The TTM is 5.919. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ0.953TTM5.919-4.967
TTM5.919YOY5.402+0.517
TTM5.9195Y250.704-244.785
5Y250.70410Y173.614+77.090
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9530.332+0.621
TTM5.9190.334+5.585
YOY5.4020.268+5.134
5Y250.7040.366+250.338
10Y173.6140.390+173.224
1.4.2. Debt to Equity Ratio

Measures if Nascent Biotech Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Nascent Biotech Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 2,011.8% means that company has $20.12 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Nascent Biotech Inc:

  • The MRQ is 20.118. The company is unable to pay all its debts with equity. -1
  • The TTM is 5.030. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ20.118TTM5.030+15.089
TTM5.030YOY-+5.030
TTM5.0305Y1.006+4.024
5Y1.00610Y0.734+0.272
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ20.1180.381+19.737
TTM5.0300.390+4.640
YOY-0.334-0.334
5Y1.0060.434+0.572
10Y0.7340.466+0.268

2. Market Valuation of Nascent Biotech Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Nascent Biotech Inc generates.

  • Above 15 is considered overpriced but always compare Nascent Biotech Inc to the Biotechnology industry mean.
  • A PE ratio of -35.72 means the investor is paying $-35.72 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Nascent Biotech Inc:

  • The EOD is -19.067. Based on the earnings, the company is expensive. -2
  • The MRQ is -35.717. Based on the earnings, the company is expensive. -2
  • The TTM is -12.669. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-19.067MRQ-35.717+16.650
MRQ-35.717TTM-12.669-23.049
TTM-12.669YOY-29.094+16.425
TTM-12.6695Y-13.178+0.509
5Y-13.17810Y-773.580+760.402
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-19.067-2.315-16.752
MRQ-35.717-2.560-33.157
TTM-12.669-2.664-10.005
YOY-29.094-4.122-24.972
5Y-13.178-6.258-6.920
10Y-773.580-6.108-767.472
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Nascent Biotech Inc:

  • The EOD is -11.864. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -22.224. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -14.259. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-11.864MRQ-22.224+10.360
MRQ-22.224TTM-14.259-7.965
TTM-14.259YOY-17.915+3.656
TTM-14.2595Y-30.165+15.906
5Y-30.16510Y-1,556.357+1,526.192
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-11.864-3.067-8.797
MRQ-22.224-3.251-18.973
TTM-14.259-3.545-10.714
YOY-17.915-5.595-12.320
5Y-30.165-8.315-21.850
10Y-1,556.357-8.708-1,547.649
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Nascent Biotech Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 966.39 means the investor is paying $966.39 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Nascent Biotech Inc:

  • The EOD is 515.892. Based on the equity, the company is expensive. -2
  • The MRQ is 966.388. Based on the equity, the company is expensive. -2
  • The TTM is -594.839. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD515.892MRQ966.388-450.497
MRQ966.388TTM-594.839+1,561.227
TTM-594.839YOY-29.529-565.310
TTM-594.8395Y-136.158-458.681
5Y-136.15810Y-1,677.000+1,540.842
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD515.8921.905+513.987
MRQ966.3882.111+964.277
TTM-594.8392.095-596.934
YOY-29.5292.836-32.365
5Y-136.1583.443-139.601
10Y-1,677.0003.794-1,680.794
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Nascent Biotech Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0000.002-89%-0.001+723%0.000+41%0.000+3412%
Book Value Per Share--0.000-0.004+2098%-0.007+3937%-0.006+3238%-0.004+2132%
Current Ratio--1.0500.568+85%0.261+302%0.265+296%0.491+114%
Debt To Asset Ratio--0.9535.919-84%5.402-82%250.704-100%173.614-99%
Debt To Equity Ratio--20.1185.030+300%-+100%1.006+1900%0.734+2640%
Dividend Per Share----0%-0%-0%-0%
Eps---0.001-0.003+155%-0.004+227%-0.003+147%-0.003+116%
Free Cash Flow Per Share---0.002-0.002-8%-0.002-16%-0.001-40%-0.001-45%
Free Cash Flow To Equity Per Share---0.0020.000-2436%0.001-373%0.000-2472%0.000-3480%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---0.068--------
Intrinsic Value_10Y_min---0.058--------
Intrinsic Value_1Y_max---0.005--------
Intrinsic Value_1Y_min---0.005--------
Intrinsic Value_3Y_max---0.016--------
Intrinsic Value_3Y_min---0.016--------
Intrinsic Value_5Y_max---0.029--------
Intrinsic Value_5Y_min---0.027--------
Market Cap15666079.000-87%29346317.00017176676.000+71%36445274.250-19%20576367.900+43%28437383.586+3%
Net Profit Margin----0%-0%0.055-100%0.038-100%
Operating Margin----0%-0%0.049-100%0.034-100%
Operating Ratio----0%-0%0.051-100%0.035-100%
Pb Ratio515.892-87%966.388-594.839+162%-29.529+103%-136.158+114%-1677.000+274%
Pe Ratio-19.067+47%-35.717-12.669-65%-29.094-19%-13.178-63%-773.580+2066%
Price Per Share0.092-87%0.1730.101+71%0.215-19%0.121+43%0.168+3%
Price To Free Cash Flow Ratio-11.864+47%-22.224-14.259-36%-17.915-19%-30.165+36%-1556.357+6903%
Price To Total Gains Ratio425.975-87%797.953254.243+214%-21.900+103%193.391+313%-445.026+156%
Quick Ratio----0%-0%0.110-100%0.076-100%
Return On Assets---0.320-2.498+680%-3.137+879%-88.489+27527%-61.853+19211%
Return On Equity---6.764-1.691-75%--100%-0.338-95%-0.345-95%
Total Gains Per Share--0.0000.002-89%-0.001+723%0.000+41%0.000+3412%
Usd Book Value--30367.000-606803.500+2098%-1165070.500+3937%-953002.150+3238%-617204.406+2132%
Usd Book Value Change Per Share--0.0000.002-89%-0.001+723%0.000+41%0.000+3412%
Usd Book Value Per Share--0.000-0.004+2098%-0.007+3937%-0.006+3238%-0.004+2132%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.001-0.003+155%-0.004+227%-0.003+147%-0.003+116%
Usd Free Cash Flow---330114.000-305227.500-8%-276993.500-16%-198551.200-40%-181361.407-45%
Usd Free Cash Flow Per Share---0.002-0.002-8%-0.002-16%-0.001-40%-0.001-45%
Usd Free Cash Flow To Equity Per Share---0.0020.000-2436%0.001-373%0.000-2472%0.000-3480%
Usd Market Cap15666079.000-87%29346317.00017176676.000+71%36445274.250-19%20576367.900+43%28437383.586+3%
Usd Price Per Share0.092-87%0.1730.101+71%0.215-19%0.121+43%0.168+3%
Usd Profit---205406.000-523291.250+155%-672379.250+227%-507200.500+147%-443985.081+116%
Usd Revenue----0%-0%87500.000-100%60344.828-100%
Usd Total Gains Per Share--0.0000.002-89%-0.001+723%0.000+41%0.000+3412%
 EOD+2 -6MRQTTM+15 -13YOY+17 -115Y+19 -1410Y+18 -15

3.2. Fundamental Score

Let's check the fundamental score of Nascent Biotech Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-19.067
Price to Book Ratio (EOD)Between0-1515.892
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than11.050
Debt to Asset Ratio (MRQ)Less than10.953
Debt to Equity Ratio (MRQ)Less than120.118
Return on Equity (MRQ)Greater than0.15-6.764
Return on Assets (MRQ)Greater than0.05-0.320
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of Nascent Biotech Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.092
Total0/1 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Total Stockholder Equity -1,36468-1,296141-1,1551,149-63730
Net Working Capital  -1,36468-1,296141-1,1551,149-63730



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets641
Total Liabilities611
Total Stockholder Equity30
 As reported
Total Liabilities 611
Total Stockholder Equity+ 30
Total Assets = 641

Assets

Total Assets641
Total Current Assets641
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 624
Total Current Assets  (as reported)641
Total Current Assets  (calculated)624
+/- 17
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities611
Long-term Liabilities0
Total Stockholder Equity30
Total Current Liabilities
Short Long Term Debt 125
Accounts payable 484
Total Current Liabilities  (as reported)611
Total Current Liabilities  (calculated)609
+/- 2
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/- 0
Total Stockholder Equity
Total Stockholder Equity (as reported)30
Total Stockholder Equity (calculated)0
+/- 30
Other
Capital Stock169
Common Stock Shares Outstanding 168,730
Net Invested Capital 155
Net Working Capital 30



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
880
900
925
5
3
117
0
110
103
131
5
5
2
3
0
99
73
751
276
105
752
105
183
1,201
566
255
79
1,043
641
6411,043792555661,201183105752105276751739903255131103110011735925900880
   > Total Current Assets 
91
130
155
2
1
117
0
110
103
131
5
5
2
3
0
99
73
751
276
105
752
105
183
1,201
566
255
79
1,043
641
6411,043792555661,20118310575210527675173990325513110311001171215513091
       Cash And Cash Equivalents 
91
130
155
2
1
117
0
110
103
131
5
5
2
3
0
99
55
1
269
102
2
94
146
1,182
559
172
9
1,004
624
6241,00491725591,182146942102269155990325513110311001171215513091
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
750
750
0
750
0
0
0
0
0
0
0
0
00000000750075075000000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18
0
7
0
0
0
0
0
0
0
0
0
0
000000000070180000000000000000
   > Long-term Assets 00000000000000000000000000000
> Total Liabilities 
194
166
221
0
1
203
1
501
595
614
626
807
954
2,879
1,398
910
1,305
1,224
1,110
1,151
1,200
777
1,620
2,389
1,930
1,551
1,234
1,049
611
6111,0491,2341,5511,9302,3891,6207771,2001,1511,1101,2241,3059101,3982,879954807626614595501120310221166194
   > Total Current Liabilities 
194
166
221
0
1
203
1
501
595
614
626
807
954
2,879
1,398
910
1,305
1,224
1,110
1,151
1,200
777
1,620
2,389
1,930
1,551
1,234
1,049
611
6111,0491,2341,5511,9302,3891,6207771,2001,1511,1101,2241,3059101,3982,879954807626614595501120310221166194
       Short-term Debt 
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
336
0
190
0
0
0
0
0
0
0
0
0
0
000000000019003360000000000000001
       Short Long Term Debt 
1
0
0
0
0
0
0
0
0
0
0
0
0
139
261
11
110
162
53
79
165
0
65
293
470
390
277
305
125
1253052773904702936501657953162110112611390000000000001
       Accounts payable 
176
152
209
0
1
203
1
466
540
526
606
677
840
853
943
715
969
637
670
597
789
777
703
765
387
498
0
510
484
4845100498387765703777789597670637969715943853840677606526540466120310209152176
       Other Current Liabilities 
17
14
12
0
0
0
0
0
0
88
0
0
115
604
165
14
434
302
250
403
95
0
836
1,331
1,072
663
313
180
0
01803136631,0721,331836095403250302434141656041150088000000121417
   > Long-term Liabilities 00000000000000000000000000000
       Deferred Long Term Liability 
0
770
770
3
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000237707700
> Total Stockholder Equity
686
734
704
4
2
-86
-1
-391
-491
-482
-621
-801
-953
-2,876
-1,397
-811
-1,232
-473
-834
-1,045
-448
-671
-1,437
-1,188
-1,364
-1,296
-1,155
-6
30
30-6-1,155-1,296-1,364-1,188-1,437-671-448-1,045-834-473-1,232-811-1,397-2,876-953-801-621-482-491-391-1-8624704734686
   Common Stock
22
23
24
0
0
28
0
31
31
33
33
34
36
45
63
67
91
105
108
108
108
111
117
118
122
0
0
0
0
00001221181171111081081081059167634536343333313102800242322
   Retained Earnings Total Equity0000000000-18,8010-18,1790000000000000000
   Accumulated Other Comprehensive Income 00000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16,856
0
17,859
0
0
0
0
0
0
0
0
0
0
000000000017,859016,8560000000000000000
   Treasury Stock00000000000000000000000000000
   Other Stockholders Equity 00000000000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-2,156
Operating Income-2,156-2,156
 
Operating Expense (+$)
Research Development271
Selling General Administrative1,502
Selling And Marketing Expenses0
Operating Expense2,1561,772
 
Net Interest Income (+$)
Interest Income0
Interest Expense-1,723
Other Finance Cost-5
Net Interest Income-1,728
 
Pretax Income (+$)
Operating Income-2,156
Net Interest Income-1,728
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-2,801-3,239
EBIT - interestExpense = -1,723
-2,801
-1,078
Interest Expense1,723
Earnings Before Interest and Taxes (EBIT)0-1,078
Earnings Before Interest and Taxes (EBITDA)-1,078
 
After tax Income (+$)
Income Before Tax-2,801
Tax Provision-0
Net Income From Continuing Ops-2,801-2,801
Net Income-2,801
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net1,0831,728
 

Technical Analysis of Nascent Biotech Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Nascent Biotech Inc. The general trend of Nascent Biotech Inc is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Nascent Biotech Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Nascent Biotech Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.19 < 0.19 < 0.28.

The bearish price targets are: 0.0825 > 0.077 > 0.075.

Tweet this
Nascent Biotech Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Nascent Biotech Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Nascent Biotech Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Nascent Biotech Inc.

Nascent Biotech Inc Daily Moving Average Convergence/Divergence (MACD) ChartNascent Biotech Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Nascent Biotech Inc. The current adx is .

Nascent Biotech Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Nascent Biotech Inc.

Nascent Biotech Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Nascent Biotech Inc.

Nascent Biotech Inc Daily Relative Strength Index (RSI) ChartNascent Biotech Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Nascent Biotech Inc.

Nascent Biotech Inc Daily Stochastic Oscillator ChartNascent Biotech Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Nascent Biotech Inc.

Nascent Biotech Inc Daily Commodity Channel Index (CCI) ChartNascent Biotech Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Nascent Biotech Inc.

Nascent Biotech Inc Daily Chande Momentum Oscillator (CMO) ChartNascent Biotech Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Nascent Biotech Inc.

Nascent Biotech Inc Daily Williams %R ChartNascent Biotech Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Nascent Biotech Inc.

Nascent Biotech Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Nascent Biotech Inc.

Nascent Biotech Inc Daily Average True Range (ATR) ChartNascent Biotech Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Nascent Biotech Inc.

Nascent Biotech Inc Daily On-Balance Volume (OBV) ChartNascent Biotech Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Nascent Biotech Inc.

Nascent Biotech Inc Daily Money Flow Index (MFI) ChartNascent Biotech Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Nascent Biotech Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-30SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-09MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-08ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-11CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-18CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-25RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-04-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Nascent Biotech Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Nascent Biotech Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.092
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Nascent Biotech Inc with someone you think should read this too:
  • Are you bullish or bearish on Nascent Biotech Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Nascent Biotech Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Nascent Biotech Inc

I send you an email if I find something interesting about Nascent Biotech Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Nascent Biotech Inc.

Receive notifications about Nascent Biotech Inc in your mailbox!